PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results [Yahoo! Finance]
PMV Pharmaceuticals, Inc. (PMVP)
Company Research
Source: Yahoo! Finance
Net Loss : Reported a net loss of $69.0 million for the year, a slight improvement from the $73.3 million loss in the previous year. R&D Investments : R&D expenses increased to $55.9 million, reflecting the company's commitment to advancing its lead drug candidate, rezatapopt. Operational Efficiency : G&A expenses decreased to $24.2 million, due to cost savings from a workforce reduction and other strategic measures. Clinical Progress : PMV Pharmaceuticals continues to progress with the PYNNACLE clinical trial for rezatapopt, with a Phase 2 trial set to initiate in Q1 2024. Corporate Developments : Appointments and strategic advisories strengthen the company's leadership in advancing its clinical programs. Warning! GuruFocus has detected 1 Warning Sign with PMVP. On February 29, 2024, PMV Pharmaceuticals Inc ( NASDAQ:PMVP ) released its 8-K filing , detailing the financial results for the full year ended December 31, 2023, and providing a corporate update. PMV Pharmaceuti
Show less
Read more
Impact Snapshot
Event Time:
PMVP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PMVP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PMVP alerts
High impacting PMV Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
PMVP
News
- PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors [Yahoo! Finance]Yahoo! Finance
- PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsGlobeNewswire
- PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer [Yahoo! Finance]Yahoo! Finance
PMVP
Earnings
- 11/9/23 - Beat
PMVP
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- PMVP's page on the SEC website